Association of IL8 polymorphisms with overall survival in patients with renal cell carcinoma in COMPARZ (pazopanib versus sunitinib phase III study)

被引：0
|
作者：
Xu, Chun-Fang
Johnson, Toby
Choueiri, Toni K.
Deen, Keith C.
Xue, Zhengyu
Spraggs, Colin F.
Bartlett-Pandite, Arundathy N.
Carpenter, Christopher
Motzer, Robert John
机构：
[1] GlaxoSmithKline, Harlow, Essex, England
[2] GlaxoSmithKline, Uxbridge, Middx, England
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] GlaxoSmithKline, Collegeville, PA USA
[5] GlaxoSmithKline, Res Triangle Pk, NC USA
[6] GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA
[7] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4519
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Effects of pazopanib (PAZ) and sunitinib (SUN) dose modification on safety and efficacy in patients with metastatic renal cell carcinoma (mRCC) from COMPARZ.
    Bjarnason, Georg A.
    Kollmannsberger, Christian K.
    Ahnnad, Qasim
    Dezzani, Luca
    Elmeliegy, Mohamed
    Han, Jackie
    Nathan, Paul D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [22] Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
    Nikic, Predrag
    Babovic, Nada
    Dzamic, Zoran
    Salma, Svetlana
    Stojanovic, Vesna
    Matkovic, Suzana
    Pejcic, Zoran
    Juskic, Kristina
    Soldatovic, Ivan
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [23] Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
    Kim, Jwa Hoon
    Park, Inkeun
    Lee, Jae Lyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 78 (02) : 325 - 332
  • [24] Pazopanib versus sunitinib for the treatment of metastatic renal cell carcinoma patients with poor-risk features
    Jwa Hoon Kim
    Inkeun Park
    Jae Lyun Lee
    Cancer Chemotherapy and Pharmacology, 2016, 78 : 325 - 332
  • [25] A phase I study of BMS-936558 plus sunitinib or pazopanib in patients with metastatic renal cell carcinoma.
    Hammers, Hans J.
    Rini, Brian I.
    Hudes, Gary R.
    Ernstoff, Marc S.
    Kollmannsberger, Christian K.
    Shen, Yun
    Waxman, Ian
    Dhar, Arindam
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
    Motzer, Robert J.
    Porta, Camillo
    Eto, Masatoshi
    Powles, Thomas
    Gruenwald, Viktor
    Hutson, Thomas E.
    Alekseev, Boris
    Rha, Sun Young
    Merchan, Jaime
    Goh, Jeffrey C.
    Lalani, Aly-Khan A.
    De Giorgi, Ugo
    Melichar, Bohuslav
    Hong, Sung-Hoo
    Gurney, Howard
    Mendez-Vidal, Maria Jose
    Kopyltsov, Evgeny
    Tjulandin, Sergei
    Gordoa, Teresa Alonso
    Kozlov, Vadim
    Alyasova, Anna
    Winquist, Eric
    Maroto, Pablo
    Kim, Miso
    Peer, Avivit
    Procopio, Giuseppe
    Takagi, Toshio
    Wong, Shirley
    Bedke, Jens
    Schmidinger, Manuela
    Rodriguez-Lopez, Karla
    Burgents, Joseph
    He, Cixin
    Okpara, Chinyere E.
    Mckenzie, Jodi
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (11) : 1222 - 1228
  • [27] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, Mian
    He, Chaosheng
    Huang, Jinkun
    Lin, Qizhan
    Zou, Lixin
    ANNALS OF ONCOLOGY, 2015, 26 : 101 - 102
  • [28] Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma
    Xie, M.
    He, C.
    Huang, J.
    ANNALS OF ONCOLOGY, 2015, 26 : 71 - 71
  • [29] Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies
    Sheng, Xinan
    Jin, Jie
    He, Zhisong
    Huang, Yiran
    Zhou, Ai-Ping
    Wang, Jinwan
    Ren, Xiu-Bao
    Ye, Dingwei
    Zhang, Xu
    Qin, Shukui
    Zhou, Fang-Jian
    Guo, Yanfang
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [30] Predictive and prognostic factors in a phase III study of pazopanib in patients with advanced renal cell carcinoma (RCC)
    Sternberg, C.
    Davis, I.
    Wagstaff, J.
    Hawkins, R.
    Chen, M.
    Ding, J.
    EJC SUPPLEMENTS, 2009, 7 (02): : 424 - 424
12345